Literature DB >> 18563460

Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies.

K Nomura1, Y Fujimoto, Y Kanbayashi, K Ikawa, M Taniwaki.   

Abstract

Voriconazole has been shown to be safe and effective for fungal infection. However, its population pharmacokinetics for patients with hematological malignancies remains unknown. We performed a population pharmacokinetics study of nine hematological patients with 36 points samples. We approximated the drug concentration curve using a linear one-compartment model. The distribution of volume (Vd), elimination rate constant, and clearance (CL) were 68.7 L, 0.163 h(-1), and 11.2 L/h, respectively. By coincidence, our study has verified that the current administration is enough to treat fungus infections by using Monte Carlo simulation. Our data demonstrated that the current administration method is appropriate and effective. Our results may prove to be useful as a basic reference for the clinical usage of voriconazole.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18563460     DOI: 10.1007/s10096-008-0543-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  Perl-speaks-NONMEM (PsN)--a Perl module for NONMEM related programming.

Authors:  Lars Lindbom; Jakob Ribbing; E Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2004-08       Impact factor: 5.428

2.  Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status.

Authors:  Yasuhiko Ikeda; Kazuo Umemura; Kazunao Kondo; Kaneo Sekiguchi; So Miyoshi; Mitsuyoshi Nakashima
Journal:  Clin Pharmacol Ther       Date:  2004-06       Impact factor: 6.875

3.  PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.

Authors:  Lars Lindbom; Pontus Pihlgren; E Niclas Jonsson; Niclas Jonsson
Journal:  Comput Methods Programs Biomed       Date:  2005-09       Impact factor: 5.428

Review 4.  Clinical pharmacokinetics of voriconazole.

Authors:  Dominique Levêque; Yasmine Nivoix; François Jehl; Raoul Herbrecht
Journal:  Int J Antimicrob Agents       Date:  2006-03-24       Impact factor: 5.283

5.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.

Authors:  Thomas J Walsh; Peter Pappas; Drew J Winston; Hillard M Lazarus; Finn Petersen; John Raffalli; Saul Yanovich; Patrick Stiff; Richard Greenberg; Gerald Donowitz; Mindy Schuster; Annette Reboli; John Wingard; Carola Arndt; John Reinhardt; Susan Hadley; Robert Finberg; Michél Laverdière; John Perfect; Gary Garber; Giuseppe Fioritoni; Eli Anaissie; Jeanette Lee
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

Review 6.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

7.  International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).

Authors:  M A Pfaller; R N Jones; G V Doern; A C Fluit; J Verhoef; H S Sader; S A Messer; A Houston; S Coffman; R J Hollis
Journal:  Diagn Microbiol Infect Dis       Date:  1999-09       Impact factor: 2.803

8.  In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

9.  Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis.

Authors:  Kenichi Nomura; Norifumi Morikawa; Kazuro Ikawa; Kayo Ikeda; Yoshiko Fujimoto; Daisuke Shimizu; Kyoko Taniguchi; Kazuho Shimura; Yuko Kanbayashi; Toshiaki Komori; Yosuke Matsumoto; Naohisa Fujita; Chihiro Shimazaki; Masafumi Taniwaki
Journal:  J Antimicrob Chemother       Date:  2008-02-13       Impact factor: 5.790

10.  In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

Authors:  D Andes; K Marchillo; T Stamstad; R Conklin
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

  10 in total
  10 in total

1.  Population pharmacokinetic evaluation with external validation and Bayesian estimator of voriconazole in liver transplant recipients.

Authors:  Kelong Han; Robert Bies; Heather Johnson; Blair Capitano; Raman Venkataramanan
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

2.  Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children.

Authors:  Sarah Allegra; Giovanna Fatiguso; Silvia De Francia; Fabio Favata; Elisa Pirro; Chiara Carcieri; Amedeo De Nicolò; Jessica Cusato; Giovanni Di Perri; Antonio D'Avolio
Journal:  Br J Clin Pharmacol       Date:  2017-09-24       Impact factor: 4.335

3.  The Impact of Model-Misspecification on Model Based Personalised Dosing.

Authors:  David A J McDougall; Jennifer Martin; E Geoffrey Playford; Bruce Green
Journal:  AAPS J       Date:  2016-06-15       Impact factor: 4.009

4.  Comparative Evaluation of the Predictive Performances of Three Different Structural Population Pharmacokinetic Models To Predict Future Voriconazole Concentrations.

Authors:  Andras Farkas; Gergely Daroczi; Phillip Villasurda; Michael Dolton; Midori Nakagaki; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

5.  External evaluation of population pharmacokinetic models for voriconazole in Chinese adult patients with hematological malignancy.

Authors:  Weikun Huang; You Zheng; Huiping Huang; Yu Cheng; Maobai Liu; Nupur Chaphekar; Xuemei Wu
Journal:  Eur J Clin Pharmacol       Date:  2022-06-28       Impact factor: 3.064

Review 6.  Voriconazole: A Review of Population Pharmacokinetic Analyses.

Authors:  Changcheng Shi; Yubo Xiao; Yong Mao; Jing Wu; Nengming Lin
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

7.  Determination of a suitable voriconazole pharmacokinetic model for personalised dosing.

Authors:  David A J McDougall; Jennifer Martin; E Geoffrey Playford; Bruce Green
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-12-16       Impact factor: 2.745

8.  Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.

Authors:  Kelong Han; B Capitano; R Bies; B A Potoski; S Husain; S Gilbert; D L Paterson; K McCurry; R Venkataramanan
Journal:  Antimicrob Agents Chemother       Date:  2010-08-02       Impact factor: 5.191

9.  Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review.

Authors:  Hannah Yejin Kim; Anne-Grete Märtson; Erwin Dreesen; Isabel Spriet; Sebastian G Wicha; Andrew J McLachlan; Jan-Willem Alffenaar
Journal:  Front Pharmacol       Date:  2020-06-12       Impact factor: 5.810

10.  Population pharmacokinetics of voriconazole and initial dosage optimization in patients with talaromycosis.

Authors:  Zhiwen Jiang; Yinyi Wei; Weie Huang; Bingkun Li; Siru Zhou; Liuwei Liao; Tiantian Li; Tianwei Liang; Xiaoshu Yu; Xiuying Li; Changjing Zhou; Cunwei Cao; TaoTao Liu
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.